Discovery of a novel third-generation EGFR inhibitor and identification of a potential combination strategy to overcome resistance
T Zhang, R Qu, S Chan, M Lai, L Tong, F Feng, H Chen… - Molecular cancer, 2020 - Springer
Background Non-small cell lung cancer (NSCLC) patients with activating EGFR mutations
initially respond to first-generation EGFR inhibitors; however, the efficacy of these drugs is …
initially respond to first-generation EGFR inhibitors; however, the efficacy of these drugs is …
Synthesis and biological evaluation of coumarine-imidazo [1, 2-c][1, 2, 3] triazoles: PEG-400 mediated one-pot reaction under ultrasonic irradiation
R Samala, SK Nukala, R Manchal, VR Nagavelli… - Journal of Molecular …, 2023 - Elsevier
Synthetic chemists have organized easy and effective ways for perfect synthesis in response
to the requirement for scaffolds that are crucial for medical applications. To investigate the …
to the requirement for scaffolds that are crucial for medical applications. To investigate the …
JAK2 inhibitor persistence in MPN: uncovering a central role of ERK activation
G Pandey, AT Kuykendall, GW Reuther - Blood Cancer Journal, 2022 - nature.com
The Philadelphia chromosome negative myeloproliferative neoplasms, including
polycythemia vera, essential thrombocytosis, and myelofibrosis, are driven by hyper …
polycythemia vera, essential thrombocytosis, and myelofibrosis, are driven by hyper …
[HTML][HTML] The prospect of combination therapies with the third-generation EGFR-TKIs to overcome the resistance in NSCLC
S Li, S Zhu, H Wei, P Zhu, Y Jiao, M Yi, J Gong… - Biomedicine & …, 2022 - Elsevier
Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) bring significant
benefits to non-small cell lung cancer patients with EGFR mutations, which represent a …
benefits to non-small cell lung cancer patients with EGFR mutations, which represent a …
Exploring the inhibitory properties of biflavonoids on α-glucosidase; computational and experimental approaches
Biflavonoids (BFs) are a group of polyphenols that have a unique biochemical structure. One
of the key biomedical mechanisms that BFs can have high potential in managing Diabetes …
of the key biomedical mechanisms that BFs can have high potential in managing Diabetes …
Nanomedicines for combating multidrug resistance of cancer
Chemotherapy typically involves the use of specific chemodrugs to inhibit the proliferation of
cancer cells, but the frequent emergence of a variety of multidrug‐resistant cancer cells …
cancer cells, but the frequent emergence of a variety of multidrug‐resistant cancer cells …
Targeting the EMT transcription factor Snail overcomes resistance to osimertinib in EGFR‐mutant non‐small cell lung cancer
Q Qin, X Li, X Liang, L Zeng, J Wang, L Sun… - Thoracic …, 2021 - Wiley Online Library
Background The resistance mechanism of the third generation of epidermal growth factor
(EGFR) tyrosine kinase inhibitor (TKI) osimertinib is complex. Epithelial mesenchymal …
(EGFR) tyrosine kinase inhibitor (TKI) osimertinib is complex. Epithelial mesenchymal …
Recruitment of hexahydroquinoline as anticancer scaffold targeting inhibition of wild and mutants EGFR (EGFRWT, EGFRT790M, and EGFRL858R)
Hexahydroquinoline (HHQ) scaffold was constructed and recruited for development of new
series of anticancer agents. Thirty-two new compounds were synthesised where x-ray …
series of anticancer agents. Thirty-two new compounds were synthesised where x-ray …
Synthesis and Biological Evaluation of Benzo [d] thiazolyl‐Sulfonyl‐Benzo [4, 5] isothiazolo [2, 3‐c][1, 2, 3] triazole Derivatives as EGFR Targeting Anticancer Agents
E Ramya Sucharitha, S Kumar Nukala… - …, 2023 - Wiley Online Library
A one‐step procedure for the synthesis of new fused Benzo [d] thiazolo‐1, 2, 3‐triazoles (3 a–
3 h and 4 a–4 h) in good yields using sulfonylazides (2) and iodoalkyne (1) through from the …
3 h and 4 a–4 h) in good yields using sulfonylazides (2) and iodoalkyne (1) through from the …
An assessment of EGFR and HER2 inhibitors with structure activity relationship of fused pyrimidine derivatives for breast cancer: a brief review
PS Dhiwar, GS Purawarga Matada, R Pal… - Journal of …, 2024 - Taylor & Francis
Epidermal growth factor receptor (EGFR) and its subtype human epidermal growth factor
receptor 2 (HER2) gets activated when its endogenous ligand (s) bind to its ATP binding site …
receptor 2 (HER2) gets activated when its endogenous ligand (s) bind to its ATP binding site …